Introduction - An Update on Asprin for DVT Prophylaxis
No me gusta!
The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.
Is lifelong anticoagulation needed to prevent recurrent clots for patients with unprovoked thromboembolic events? Yes, usually. Patients with large idiopathic PEs and most with idiopathic proximal DVTs should have lifelong anticoagulation. The recurrence risk is 20-30% in 5 years. Treatment with warfarin or one of the newer anticoagulants reduces the thrombosis risk by 80-90%.
Some women with no risk factors (not obese, younger than 65, D-dimer on therapy is normal) may not need to be chronically anticoagulated with warfarin.
Does aspirin provide any benefit? Yes, but it’s not as powerful.
The INSPIRE Collaboration looked at over 1200 patients with first episode unprovoked thromboembolic events. After completing treatment for their thromboses, patients were treated with either low dose aspirin or placebo and followed for 2 ½ years. Compared to placebo, aspirin reduced the risk of recurrent DVT and PE by 32% per year. There was no statistically significant increased risk of bleeding with aspirin therapy.
For patients with unprovoked DVT or PE history who will not receive indefinite warfarin or a newer anticoagulant therapy, consider low dose aspirin to reduce the recurrent thrombosis risk.